Key result
Type 2 myocardial infarction was associated with a higher 5-year all-cause death rate compared to type 1 myocardial infarction with an adjusted RR of 1.51.
Why the study?
Does the diagnosis of type 2 myocardial infarction or myocardial injury increase the risk of all-cause mortality and cardiovascular events compared to type 1 myocardial infarction in hospitalized patients?
Cohort (n=2,122)
No
Does the diagnosis of type 2 myocardial infarction or myocardial injury increase the risk of all-cause mortality and cardiovascular events compared to type 1 myocardial infarction in hospitalized patients?
Answers are grounded in this paper and cite their sources.
Although excess mortality in type 2 MI and myocardial injury is largely driven by noncardiovascular death, these patients face long-term major adverse cardiovascular event rates similar to those with type 1 MI, underscoring a need for targeted cardiovascular evaluation and secondary prevention.
BACKGROUND: Type 2 myocardial infarction and myocardial injury are common in clinical practice, but long-term consequences are uncertain. We aimed to define long-term outcomes and explore risk stratification in patients with type 2 myocardial infarction and myocardial injury. METHODS: We identified consecutive patients (n=2122) with elevated cardiac troponin I concentrations (≥0.05 µg/L) at a tertiary cardiac center. All diagnoses were adjudicated as per the universal definition of myocardial infarction. The primary outcome was all-cause death. Secondary outcomes included major adverse cardiovascular events (eg, nonfatal myocardial infarction or cardiovascular death) and noncardiovascular death. To explore competing risks, cause-specific hazard ratios were obtained using Cox regression models. RESULTS: The adjudicated index diagnosis was type 1 or 2 myocardial infarction or myocardial injury in 1171 (55.2%), 429 (20.2%), and 522 (24.6%) patients, respectively. At 5 years, all-cause death rates were higher in those with type 2 myocardial infarction (62.5%) or myocardial injury (72.4%) compared with type 1 myocardial infarction (36.7%). The majority of excess deaths in those with type 2 myocardial infarction or myocardial injury were because of noncardiovascular causes (hazard ratio, 2.32; 95% confidence interval, 1.92-2.81 versus type 1 myocardial infarction). Despite this finding, the observed crude major adverse cardiovascular event rates were similar between groups (30.6% versus 32.6%), with differences apparent after adjustment for covariates (hazard ratio, 0.82; 95% confidence interval, 0.69-0.96). Coronary heart disease was an independent predictor of major adverse cardiovascular events in those with type 2 myocardial infarction or myocardial injury (hazard ratio, 1.71; 95% confidence interval, 1.31-2.24). CONCLUSIONS: Despite an excess in noncardiovascular death, patients with type 2 myocardial infarction or myocardial injury have a similar crude rate of major adverse cardiovascular events as those with type 1 myocardial infarction. Identifying underlying coronary heart disease in this vulnerable population may help target therapies that could modify future risk.
No takes yet. Share an insight, caveat, or question.
Chapman et al. (2017) conducted a cohort in Elevated cardiac troponin I concentrations (≥0.05 µg/L) (n=2,122). Type 2 myocardial infarction vs. Type 1 myocardial infarction was evaluated on All-cause death (adjusted RR 1.51, 95% CI 1.21-1.87). Type 2 myocardial infarction was associated with a higher 5-year all-cause death rate compared to type 1 myocardial infarction with an adjusted RR of 1.51.
Synapse has enriched 10 related papers. Consider them for comparative context: